219
Views
0
CrossRef citations to date
0
Altmetric
Review

Advances in the pharmacological management of neutropenia in solid tumors: the advent of biosimilars

, , ORCID Icon, , , & show all
Pages 857-865 | Received 20 May 2020, Accepted 06 Jan 2021, Published online: 12 Feb 2021

References

  • Atkinson TM, Ryan SJ, Bennett AV, et al. The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review. Support Care Cancer. 2016;24(8):3669–3676.
  • Klastersky J, de Naurois J, Rolston K, et al. ESMO Guidelines Committee. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016;27:111–118.
  • Mehta H, Malandra M, Corey S. G-CSF and GM-CSF in neutropenia. J Immunol. 2015;195:1341–1349.
  • Gladkov O, Moiseyenko V, Bondarenko IN, et al. Phase II dose-finding study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy. Med Oncol. 2015;32:623.
  • Fukunaga R, Ishizaka-Ikeda E, Seto Y, et al. Expression cloning of a receptor for murine granulocyte colony-stimulating factor. Cell. 1990;61:341–350.
  • Ghidini M, Hahne JC, Trevisani F, et al. New developments in the treatment of chemotherapy-induced neutropenia: focus on balugrastim. Ther Clin Risk Manag. 2016;12:1009–1015.
  • Schroder CP, de Vries EG, Mulder NH, et al. Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients: no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B. J Antimicrob Chemother. 1999;43:741–743.
  • Smith TL, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC growth factors: american Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2015;33:3199–3212.
  • Aapro MS, Cameron DA, Pettengell R, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer. 2006;42:2433–2453.
  • Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47:8–32.
  • Becker PS, Griffiths EA, Alwan LM, et al. NCCN Guidelines Insights: hematopoietic Growth Factors, Version 1. J Natl Compr Canc Netw. 2020;18:12–22. 2020
  • Crawford J, Caserta C, Roila F, et al. Hematopoietic growth factors: ESMO clinical practice guidelines for the applications. Ann Oncol. 2010;21:248–251.
  • Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropenia: ESMO clinical practice guideline. Ann Oncol. 2016;27(suppl5):111–118.
  • Ratti M, Tomasello G. Lipegfilgrastim for the prophylaxis and treatment of chemotherapy-induced neutropenia. Expert Rev Clin Pharmacol. 2015;8:15–24.
  • Ria R, Gasparre T, Mangialardi G, et al. Comparison between filgrastim and lenograstim plus chemotherapy for mobilization of PBPCs. Bone Marrow Transplant. 2010;45:277–281.
  • Pfeil AM, Allcott K, Pettengell R, et al. Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review. Support Care Cancer. 2015;23:525–545.
  • Guideline on similar biological medicinal products containing recombinant granulocyte-colony stimulating factor (rG-CSF), EMEA/CHMP/BMWP/31329/2005 Rev 1, 2018. Available at: http://www.ema.europa.eu [Last accessed 2020 May 17th
  • GH DDC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol. 2003;21:4524–4531.
  • Patel D, Gillis C, Naggar J, et al. The rise of biosimilars: how they got there and where they are going. Metabolism. 2017;75:45–53.
  • Lyman GH, Kuderer N, Greene J, et al. The economics of febrile neutropenia: implications for the use of colony- stimulating factors. Eur J Cancer. 1998;34:1857–1864.
  • Webster J, Lyman GH. Use of G-CSF to sustain dose intensity in breast cancer patients receiving adjuvant chemotherapy: a pilot study. Cancer Control. 1996;3:519–523.
  • Aapro MS, Bohlius J, Cameron DA, et al. 2010 Update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47:8–32.
  • Smith TJ, Khatcheressian J, Lyman GH, et al. update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24:3187–3205. 2006. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103353s5184lbl.pdf
  • Sung L, Nathan PC, Alibhai SM, et al. Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infections. Ann Intern Med. 2007;147:400–411.
  • Welte K. G-CSF: filgrastim, lenograstim and biosimilars. Expert Opin Biol Ther. 2014;14:983–993.
  • Yang BB, Savin MA, Green M. Prevention of chemotherapy-induced neutropenia with pegfilgrastim: pharmacokinetics and patient outcomes. Chemotherapy. 2012;58:387–398.
  • Bennett CL, Djulbegovic B, Norris LB, et al. Colony-stimulating factors for febrile neutropenia during cancer therapy. N Engl J Med. 2013;368:1131–1139.
  • Neupogen ® (filgrastim) [prescribing information]. Thousand Oaks, CA: Amgen Inc; 2012.
  • Neulasta ® (pegfilgrastim) [prescribing information]. Thousand Oaks, CA: Amgen Inc; 2012. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125031s180lbl.pdf
  • Clark OA, Lyman GH, Castro AA, et al. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol. 2005;23:4198–4214.
  • Kuderer NM, Dale DC, Crawford J, et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25:3158–3167.
  • Cooper KL, Madan J, Whyte S, et al. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer. 2011;11:404.
  • Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small- cell lung cancer. N Engl J Med. 1991;325:164–170.
  • Heil G, Hoelzer D, Sanz MA, et al. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood. 1997;90:4710–4718.
  • Clemons M, Fergusson D, Simos D, et al. A multicentre, randomized trial comparing schedules of G-CSF (filgrastim) administration for primary prophylaxis of chemotherapy-induced febrile neutropenia in early stage breast cancer. Annals Oncol. 2020;31:951–957.
  • Pinto L, Liu Z, Doan Q, et al. Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Curr Med Res Opin. 2007;23:2283–2295.
  • Holmes FA, Jones SE, O’Shaughnessy J, et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol. 2002;13:903–909.
  • Green MD, Koelbl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 2003;14:29–35.
  • Naeim A, Henk HJ, Becker L, et al. Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF). BMC Cancer. 2013;13:11.
  • George S, Yunus F, Case D, et al. Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin’s lymphoma. Leuk Lymphoma. 2003;44:1691–1696.
  • Brusamolino E, Rusconi C, Montalbetti L, et al. Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. Haematologica. 2006;91:496–502.
  • Neulasta® (pegfilgrastim) Onpro® kit. [Healthcare Provider Instructions for Use]. Thousand Oaks, CA: Amgen Inc; 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125031s189s191lbl.pdf
  • European Medicines Agency. Granocyte® (lenograstim): EU summary of product characteristics. Chugai Pharmaceutical Co.; 2009. https://www.medicines.org.uk/emc/product/1577/smpc#gref
  • Holloway CJ. Applications of recombinant DNA technology in the production of glycosylated recombinant human granulocyte colony stimulating factor. Eur J Cancer. 1994;30A:2–6.
  • Chamorey AL, Magne N, Pivot X. Impact of glycosylation on the effect of cytokines. A special focus on oncology. Eur Cytokine Netw. 2012;13:154–160.
  • Swanson G, Bergstrom K, Stump E, et al. Growth factor usage patterns and outcomes in the community setting: collection through a practice-based computerized clinical information system. J Clin Oncol. 2000;18:1764–1770.
  • Falandry C, Campone M, Cartron G, et al. Trends in G-CSF use in 990 patients after EORTC and ASCO guidelines. Eur J Cancer. 2010;46:2389–2398.
  • Sourgens H, Lefrere F. A systematic review of available clinical evidence – filgrastim compared with lenograstim. Int J Clin Pharmacol Ther. 2011;49:510–518.
  • Lonquex ®. Summary of Product Characteristics. London: European Medicines Agency; 2013.
  • Bondarenko I, Gladkov OA, Elsaesser R, et al. Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy. BMC Cancer. 2013;13:386.
  • Gladkov OA, Buchner A, Bias P, et al. Chemotherapy- associated treatment burden in breast cancer patients receiving lipegfilgrastim or pegfilgrastim: secondary efficacy data from a phase III study. Support Care Cancer. 2016;24:395–400.
  • Bondarenko IM. Bias P and Buchner A. Incidence of bone pain in patients with breast cancer treated with lipegfilgrastim or pegfilgrastim: an integrated analysis from phase II and III studies. Support Care Cancer. 2016;24:267–273.
  • Gladkov O, Moiseyenko V, Bondarenko IN, et al. Phase II dose-finding study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy. Med Oncol. 2015;32:623.
  • Gladkov O, Moiseyenko V, Bondarenko IN, et al. A phase III study of balugrastim versus pegfilgrastim in breast cancer patients receiving chemotherapy with doxorubicin and docetaxel. Oncologist. 2016;21:7–15.
  • Volovat C, Gladkov OA, Bondarenko IM, et al. Efficacy and safety of balugrastim compared with pegfilgrastim in patients with breast cancer receiving chemotherapy. Clin Breast Cancer. 2014;14:101–108.
  • Engranli: withdrawal of the marketing authorisation application. Available at: http://www.ema.europa.eu. [Last accessed 2020 Oct 7th]
  • Roth K, Lehnick D, Wessels H, et al. Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Pelmeg®, a pegfilgrastim biosimilar in healthy subjects. Pharmacol Res Perspect. 2019;7:e00503.
  • Sorgel F, Schwebig A, Holzmann J, et al. Comparability of biosimilar filgrastim with originator filgrastim: protein characterization, pharmacodynamics, and pharmacokinetics. Biodrugs. 2015;29:123–131.
  • Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov. 2003;2:214–221.
  • Zündorf I, Dingermann T. PEGylation – a well-proven strategy for the improvement of recombinant drugs. Pharmazie. 2014;69:323–326.
  • Veronese FM, Mero A. The impact of PEGylation on biological therapies. Biodrugs. 2008;22:315–329.
  • Choi C, Yoo BW, Kim CO, et al. Comparison of biosimilar filgrastim with a reference product: pharmacokinetics, pharmacodynamics, and safety profiles in healthy volunteers. Drug Des Devel Ther. 2018;12:2381–2387.
  • Willis F, Pettengell R. Pegfilgrastim. Expert Opin Biol Ther. 2002;2:985–992.
  • Yang BB, Kido A. Pharmacokinetics and pharmacodynamics of pegfilgrastim. Clin Pharmacokinet. 2011;50:295–306.
  • Zamboni WC. Pharmacokinetics of pegfilgrastim. Pharmacotherapy. 2003;23:9–14.
  • Höglund M. Glycosylated and non-glycosylated recombinant human granulocyte colony-stimulating factor (rhG-CSF)–what is the difference? Med Oncol. 1998;15:229–233.
  • Ribeiro D, Veldwijk MR, Benner A, et al. Differences in functional activity and antigen expression of granulocytes primed in vivo with filgrastim, lenograstim, or pegfilgrastim. Transfusion. 2007;47:969–980.
  • Ataergin S, Arpaci F, Turan M, et al. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation. Am J Hematol. 2008;83(8):644–648.
  • Orciuolo E, Buda G, Marturano E, et al. Lenograstim reduces the incidence of febrile episodes, when compared with filgrastim, in multiple myeloma patients undergoing stem cell mobilization. Leuk Res. 2011;35:899–903.
  • Ria R, Gasparre T, Mangialardi G, et al. Comparison between filgrastim and lenograstim plus chemotherapy for mobilization of PBPCs. Bone Marrow Transplant. 2010;45:277–281.
  • Ria R, Reale A, Melaccio A, et al. Filgrastim, lenograstim and pegfilgrastim in the mobilization of peripheral blood progenitor cells in patients with lymphoproliferative malignancies. Clin Exp Med. 2015;15:145–150.
  • Sourgens H, Lefrère F. A systematic review of available clinical evidence - filgrastim compared with lenograstim. Int J Clin Pharmacol Ther. 2011;49:510–518.
  • Mahlert F, Schmidt K, Allgaier H, et al. Rational development of lipegfilgrastim, a novel long-acting granulocyte colony-stimulating factor, using glycopegylation technology. Blood. 2013;122(21):4853.
  • Scheckermann C, Schmidt K, Abdolzade-Bavil A, et al. Lipegfilgrastim: a long-acting, once-per-cycle, glycopegylated recombinant human filgrastim. J Clin Oncol. 2013;31(Suppl15):e13548.
  • Bond TC, Szabo E, Gabriel S, et al. Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events. J Oncol Pharm Pract. 2018;24:412–423.
  • Abdolzade-Bavil A, Cooksey BA, Scheckermann C, et al. Pegylated versus glycopegylated G-CSFs and their biochemical and physiological properties. Blood. 2013;122:4851.
  • Abdolzade-Bavil A, von Kerczek A, Cooksey BA, et al. Differential sensitivity of lipegfilgrastim and pegfilgrastim to neutrophil elastase correlates with differences in clinical pharmacokinetic profile. J Clin Pharmacol. 2016;56:186–194.
  • Dale DC, Crawford J, Klippel Z, et al. A systematic literature review of the efficacy, effectiveness, and safety of filgrastim. Support Care Cancer. 2018;26:7–20.
  • Tholpady A, Chiosea I, Lyons JJ, et al. Systemic hypersensitivity reaction mimicking anaphylaxis after first filgrastim administration in a healthy donor. Transfusion. 2013;53(5):1146–1147.
  • Akyol G, Pala C, Yildirim A, et al. A rare but sever complication of filgrastim in a healthy donor: splenic rupture. Transfus Apher Sci. 2014;50:53–55.
  • Martin WG, Ristow KM, Habermann TM, et al. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin’s lymphoma. J Clin Oncol. 2005;23:7614–7620.
  • Herrman F, Shulz G, Lindermann A, et al. Yeast-expressed granulocyte-macrophage colony-stimulating factor in cancer patients: aphase Ib clinical study. In: Behring Inst Mitt. 1988. p. 107–118. https://pubmed.ncbi.nlm.nih.gov/2467645/
  • .U.S. Food and Drug Administration. Sargramostim label information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103362s5240lbl.pdf. [Last accessed 2020 May 17th]
  • Jeong GH, Lee KH, Lee IR, et al. Incidence of Capillary Leak Syndrome as an Adverse Effect of Drugs in Cancer Patients: A Systematic Review and Meta-analysis. J Clin Med. 2019;8:E143.
  • Hadji P, Kostev K, Schroder-Bernhardi D, et al. Cost comparison of outpatient treatment with granulocyte colony-stimulating factors (G-CSF) in Germany. Int J Clin Pharmacol Ther. 2012;50:281–289.
  • Guideline on similar biological medicinal products containing recombinant granulocyte-colony stimulating factor (rG-CSF), EMEA/CHMP/BMWP/31329/2005 Rev 1. (2018). Available at: http://www.ema.europa.eu. [Last accessed 2020 May 17th]
  • Wolff-Holz E, Tiitso K, Vleminckx C, et al. Evolution of the AU Biosimilar Framework: past and Future. BioDrugs. 2019;33:621–634.
  • Derbyshire M. Patent expiry dates for biologicals: 2018 update. GaBI J. 2019;8:24–31.
  • Biosimilar G-CSF prescribed more than originator. Mol, Belgium: pro Pharma Communications International. Available at: www.gabionline.net/Biosimilars/News/Biosimilar-G-CSF-prescribed-more-than-originator. [Last accessed 2020 May 17th]
  • Blackwell K, Gascon P, Krendyukov A, et al. Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase 3, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive therapy. Ann Oncol. 2018;29:244–249.
  • Harbeck N, Gascon P, Krendyukov A, et al. Safety profile of biosimilar filgrastim (Zarzio/Zarxio): a combined analysis of phase III studies. Oncologist. 2018;23:403–409.
  • Zecchini J, Yum K, Steinberg A, et al. A single-center, retrospective analysis to compare the efficacy and safety of filgrastim-sndz to filgrastim for prophylaxis of chemotherapy-induced neutropenia and for neutrophil recovery during following autologous stem cell transplantation. Support Care Cancer. 2017;26:1013–1016.
  • Chen X, Agiro A, Barron J, et al. Early adoption of biosimilar growth factor in supportive cancer care. JAMA Oncol. 2018;4:1779–1781.
  • .Waller CF, Semiglazov VF, Tjulandin S, et al. A phase III randomized equivalence study of biosimilar filgrastim versus Amgen filgrastim in patients receiving myelosuppressive chemotherapy for breast cancer. Onkologie. 2010;33:504–511.
  • Fruehauf S, Otremba B, Stotzer O, et al. Compatibility of biosimilar filgrastim with cytotoxic chemotherapy during the treatment of malignant diseases (VENICE): a prospective, multicenter, non-interventional, longitudinal study. Adv Ther. 2016;33:1983–2000.
  • Brito M, Esteves S, Andre R, et al. Comparison of effectiveness of biosimilar filgrastim (Nivestim) reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with (neo)adjuvant TAC: a non-interventional cohort study. Support Care Cancer. 2016;24:597–603.
  • Frederic M, Stephane L, Didier K, et al. Biosimilar filgrastim in the treatment and the prevention of chemotherapy-induced neutropenia: the next study. J Geriatr Oncol. 2014;5:S71.
  • Waller CF, Tiessen RG, Lawrence TE, et al. A pharmacokinetics and pharmacodynamics equivalence trial of the proposed pegfilgrastim biosimilar, MYL-1401H, versus reference pegfilgrastim. J Cancer Res Clin Oncol. 2018;144:1087–1095.
  • Waller CF, Ranganna GM, Pennella EJ, et al. Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia. Ann Hematol. 2019;98:1217–1224.
  • Waller CF, Ranganna GM, Pennella EJ, et al. Comparison of immunogenicity between the proposed pegfilgrastim biosimilar MYL-1401H and reference pegfilgrastim. Blood. 2017;130:3568.
  • Glaspy JA, O’Connor PG, Tang H, et al. Randomized, single-blind, crossover study to assess the pharmacokinetic and pharmacodynamic bioequivalence of CHS-1701 to pegfilgrastim in healthy subjects. J Clin Oncol. 2017;35:e21693.
  • Harbeck N, Lipatov O, Frolova M, et al. Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer. Future Oncol. 2016;12:1359–1367.
  • Blackwell K, Donskih R, Jones CM, et al. A comparison of proposed biosimilar LA-EP2006 and reference pegfilgrastim for the prevention of neutropenia in patients with early-stage breast cancer receiving myelosuppressive adjuvant or neoadjuvant chemotherapy: pegfilgrastim randomized oncology (supportive care) trial to evaluate comparative treatment (PROTECT-2), a phase III, randomized, double-blind trial. Oncologist. 2016;21:789–794.
  • Möbus V, Jackisch C, Lück HJ, et al. Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial. Ann Oncol. 2018;29:178–185.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.